Prior Exposure to Lamivudine Increases Entecavir Resistance Risk in Chronic Hepatitis B Patients without Detectable Lamivudine Resistance

The efficacy of entecavir (ETV) treatment in chronic hepatitis B (CHB) patients who were exposed to lamivudine (LAM) but had no detectable LAM resistance (LAM-R) is not well evaluated. In this study, we aimed to evaluate whether the probability of developing genotypic resistance to ETV in LAM-expose...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Lee, Jeong-Hoon, Cho, Yuri, Lee, Dong Hyeon, Lee, Minjong, Yoo, Jeong-ju, Choi, Won-mook, Cho, Young Youn, Lee, Yun Bin, Yu, Su Jong, Yoon, Jung-Hwan, Lee, Hyo-Suk, Kim, Yoon Jun
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2014
Assuntos:
Antiviral Agents
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3957876/
https://ncbi.nlm.nih.gov/pubmed/24395227
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02483-13
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados